Browse
Submit Data
Databases
API
Help

Dataset Information

12 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Impact of anti-tumor necrosis factors antibodies treatment on fertility of inflammatory bowel diseases male patients

ABSTRACT: Primary objectives: To assess the impact of antiTNF agents on the male inflammatory bowel diseases patients` fertility Primary outcomes:- semen quality and quantity, inclusive sperm chromatine structure analysis prior and during anti-TNF therapy- time to conception

DISEASE(S): Fertility Influenced By Antitnf Treatment,Fertility Investigations

PROVIDER: 2525194 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Safety of Anti-tumor Necrosis Factor (TNF) Monoclonal Antibodies in Inflammatory Bowel Disease

Project description:Anti-TNF (tumor necrosis factor) monoclonal antibodies have revolutionized management of Inflammatory bowel disease. Their common features include high efficacy but also immunogenicity and increased infection risk. Since 2013, two generics or biosimilars of the first anti-TNF have been registered in Europe, which long lerm safety profile needs yet to be established. This prospective, multicenter, observational cohort study will assess safety of treatment of anti-TNF monoclonal antibodies in inflammatory bowel disease patients in Poland. Eligible are consecutive patients in whom anti-TNF is started for Crohn’s disease, ulcerative colitis or indeterminate colitis between January 1st, 2014 and December 31st, 2015. Data to be collected include demography, Montreal classification, indication to treatment, previous treatment, operations, extraintestinal manifestations and concomitant diseases. Data on response, tolerability and safety of anti-TNF and on concomitant treatment will be collected. Adverse events logs will be completed. Majority of IBD centres in Poland, pediatric and adult, academic and regional, have agreed to participate in the study. As a result of the study, the frequency of adverse events in a cohort of Polish IBD patients on various anti-TNFs will be established.

| 2161078 | ecrin-mdr-crc

Sub-optimal Response to Anti-Tumor Necrosis Factor’s in Inflammatory Bowel Disease in Emerging Markets

Project description:The purpose of this study is to establish the incidence of sub-optimal response to anti-TNF therapy in UC and CD participants.

| 2239539 | ecrin-mdr-crc

HD-ZIP IV transcription factor OCL4 and 21-nt phasiRNAs are dispensable for male fertility in maize anthers

Project description:The maize ocl4 mutants showed differing levels of male sterility, which seems correlating with the quantity of 21-nt phasiRNA remaining during pre-meiotic stage. In this case, sRNA and transcriptome was profiled and compared in this study, showed that OCL4 and 21-nt phasiRNAs are dispensable for male fertility in maize anthers.

2021-09-09 | GSE150446 | GEO

Novel Pharmacological Therapy in Inflammatory Bowel Diseases: Beyond Anti-Tumor Necrosis Factor.

Project description: Not available

| S-EPMC6611384 | biostudies-literature

Risk of tuberculosis in Korean inflammatory bowel disease patients treated with Tumor Necrosis Factor-a (TNF-a) blockers

Project description:Primary outcome(s): Quantification of the incidence rate of TB in IBD patients treated with TNF-a blockers and compared that with general population rates Study Design: Observational Study Model : Cohort, Time Perspective : Retrospective, Enrollment : 1000, Biospecimen Retention : Not collect nor Archive

| 2509453 | ecrin-mdr-crc

TAK1: a potent tumour necrosis factor inhibitor for the treatment of inflammatory diseases.

Project description: Not available

| S-EPMC7536066 | biostudies-literature

PK Bioequivalence Single-dose Safety Tolerability Study in Healthy Male Volunteers to Compare CBT124 & Avastin(EU&US)

Project description:This study aims to investigate the bioequivalence of new formulation of bevacizumab called CBT124 and safety when compared to two already marketed formulations, one approved in US and other in EU of Avastin(Registered Trademark). Adult healthy male aged 18 to 50 years (both inclusive) can participate in this trial. Participants will be randomised (allocated by chance) to either a test formulation or one of the two marketed formulations of bevacizumab. Drugs will be administered intravenously once only. The study will compare the safety, tolerability, pharmacokinetics (PK) (the levels of drug in the blood), pharmacodynamics (PD) (what the drug does to the body) and immunogenicity (body’s immune response) of the 3 drugs. In order to measure this, blood samples will be collected at various points after treatment has been given.

| 2213278 | ecrin-mdr-crc

Pre-treatment With Azithromycin to Reduce Immunogenicity to Anti-Tumor Necrosis Factor-α Agents in Patients With Inflammatory Bowel Disease

Project description:This will be a randomized placebo-controlled trial in inflammatory bowel disease patients before initiation of anti-tumor necrosis factor-α (anti-TNF) therapy that aims to test the effect of a pre-treatment short course of azithromycin therapy on immunogenicity

| 2752894 | ecrin-mdr-crc

Therapeutic use of specific tumour necrosis factor inhibitors in inflammatory diseases including COVID-19.

Project description: Not available

| S-EPMC8162906 | biostudies-literature

Cell death and inflammatory bowel diseases: apoptosis, necrosis, and autophagy in the intestinal epithelium.

Project description: Not available

| S-EPMC4121991 | biostudies-literature